Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis
Authors:
- 1 August 2020
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 146 (2)
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening syndrome classified into primary HLH and secondary HLH. Secondary HLH is always caused by autoimmune disease, infections, or cancer. The first-line therapy for secondary HLH is the HLH 2004 protocol, including dexamethasone, etoposide, and supportive therapy. However, up to 30% of patients, especially pediatric patients, remain unresponsive to first-line treatment, and the mortality rate reaches 50% in children with HLH. Furthermore, some children who have special conditions, such as an active virus infection, are not suitable for immunosuppressants treatment. Recently, several HLH-promoting cytokines have been identified, including interferon-γ, interleukin-2, and interleukin-6. Janus kinase 1 and 2 control the signaling of many cytokines, notably interferon-γ, interleukin-2, and interleukin-6. Janus kinase 1 and 2 inhibitors, such as ruxolitinib, have been successfully used to treat HLH in mice. Here, we report that a boy, diagnosed with HLH and high titer of hepatitis B virus–DNA copies, improved quickly, and the cytokine storm of HLH was alleviated after receiving ruxolitinib. Five days after ruxolitinib treatment, entecavir was introduced and serum titer results of hepatitis B virus–DNA returned negative. With 3 months of ruxolitinib treatment and following-up 1 year, the boy’s situation maintained sustained remission. In this study, it is suggested that ruxolitinib might be a first-line drug, which could alleviate the cytokine storm of HLH. This treatment may be ushering in the age of glucocorticosteroid-free HLH treatment, which is particularly meaningful for children because it avoids the side effects of glucocorticosteroid.Keywords
This publication has 13 references indexed in Scilit:
- Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosisBlood Advances, 2017
- Use of a mouse model to identify a blood biomarker for IFNγ activity in pediatric secondary hemophagocytic lymphohistiocytosisTranslational Research, 2017
- Associations between inflammatory cytokines and organ damage in pediatric patients with hemophagocytic lymphohistiocytosisCytokine, 2016
- Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in miceBlood, 2016
- Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosisBlood, 2016
- A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)Pediatric Blood & Cancer, 2015
- Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosisAmerican Journal of Hematology, 2014
- Secondary hemophagocytic lymphohistiocytosis possibly induced by interferon beta-1a therapy.Reumatismo, 2013
- JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated DiseaseImmunity, 2012
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2006